FDA Designates Pracinostat Orphan Drug for AML

Share this content:
FDA Designates Pracinostat Orphan Drug for Acute Myeloid Leukemia
FDA Designates Pracinostat Orphan Drug for Acute Myeloid Leukemia

MEI Pharma announced that the FDA has granted Orphan Drug designation to Pracinostat for the treatment of acute myeloid leukemia (AML). Pracinostat is an orally available histone deacetylase (HDAC) inhibitor.

Pracinostat has been tested in numerous Phase 1 and Phase 2 clinical trials in advanced hematologic disorders and solid tumor indications in both adult and pediatric patients. In a Phase 1 dose-escalation trial, Pracinostat demonstrated evidence of single-agent activity in elderly AML patients, including 2 out of 14 (14%) who achieved a complete remission (CR), with durable responses persisting 206+ and 362 days, respectively.

RELATED: Hematologic Cancers Resource Center

MEI Pharma is currently conducting a Phase 2 clinical trial of Pracinostat in combination with Vidaza (azacitidine) in elderly patients with newly diagnosed AML. Preliminary data from the open-label trial is anticipated to be released in December 2014.

For more information call (858) 792-6300 or visit MEIPharma.com.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs